Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

Kaplan, David L.; Husni, Elaine; Chang, Eunice; Broder, Michael S.; Paydar, Caleb; Bognar, Katalin; Yan, Jessie T.; Richter, Sven; Desai, Pooja; Khilfeh, Ibrahim

doi:10.2217/cer-2021-0311

Cited by 1 publication

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a prior study (2005–2015), time from commencement of systemic therapy to the initiation of biologics was 6.8 years, which is in accordance with the 5.5 years of this study, but other studies have reported short time to biologics 8,9 . Surprisingly, we did not observe a decrease in time to first biologic therapy after introduction of biosimilars and observed a slight increase or no change at all.…”

Section: Discussionsupporting

confidence: 91%

“…In a prior study (2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015), time from commencement of systemic therapy to the initiation of biologics was 6.8 years, which is in accordance with the 5.5 years of this study, but other studies have reported short time to biologics. 8,9 Surprisingly, we did not observe a decrease in time to first biologic therapy after introduction of biosimilars and observed a slight increase or no change at all. The reasons for this remain unclear but could reflect that biologic therapies became more accessible to moderate disease severity who would otherwise have continued systemic treatment.…”

Section: Discussioncontrasting

confidence: 66%

See 1 more Smart Citation

Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study

Thein,

Rosenø,

Nielsen

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundLimited research has been conducted on whether advances in novel biologics and biosimilars have improved the treatment journey preceding biologics.ObjectivesTo map the overall treatment journey preceding the initiation of first biologic therapy in patients with psoriasis (PsO) and psoriatic arthritis (PsA), as well as the changes over time.MethodsUsing Danish nationwide registries, we included all patients treated with a first‐time biologic (2010–2018) for either PsO or PsA and reported the medical treatment journey. We used Sankey diagrams to illustrate the flow of treatment series.ResultsThe study included 2082 patients with PsO (62.5% male) and 1831 patients with PsA (42.3% male). Before biologics, 49.5% treated for PsO and 36.8% treated for PsA received ≥2 type therapies and 59.3% with PsO and 25.5% with PsA received ≥3 treatment series. Median time from first systemic therapy to a biologic was 3.9 years (Q1–Q3, 1.3–4.1) for PsO and 2.1 years (Q1–Q3, 0.6–5.8) for PsA. The majority of patients with PsO (1174 [56.4%]) received multiple treatment series with the same drug, while almost a third of patients with PsA (572 [31.2%]) did the same. Twelve percent of patients with PsO and 6.4% of patients with PsA repeated treatment with a drug they had already stopped for an alternative treatment.ConclusionsAlthough most patients are adequately managed, our findings suggest the possibility of a yet too long and complicated treatment journey before starting biologics.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 66%